Home
| Log in or Sign Up for full access
| Tracked Organizations
| Recent Tracked Activities
Recent Activities
Activities between Nov. 15, 2024, 11:56 p.m. and Nov. 22, 2024, 11:56 p.m.
from: Ophthalmic Lens And Eyewear.
Click on a document link to see the original source document.
Click on the name of an organization to see more organization linkages and timelines.
Document Date: Nov. 22, 2024, noon / Source: GlobeNewswire
Activity Class: CorporateFinanceActivity
/ Type: Bankruptcy
/ Region: New York City
Vendor:
- Eyenovia
/ Industry: Biopharmaceutical And Biotech Industry, Hospital Management Service and 2 more
Document Extract: NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) - Eyenovia, Inc. (NASDAQ: EYEN) , an ophthalmic technology company, today provided an update on its ongoing restructuring efforts.
Document Source: https://www.globenewswire.com/news-release/2024/11/22/2985852/0/en/Eyenovia-Provides-Update-on-Restructuring-Efforts.html
(archive.org page /
archive.org listing)
Document Date: Nov. 18, 2024, 2 p.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership:
Document Extract: Zenni Optical and NBA Star Jrue Holiday Team Up to Launch Exclusive Eyewear Collection. Zenni partners with Jrue Holiday, the star guard, 2x NBA champion, 2x All-Star and 2x Olympian for a Stylish Eyewear Launch Featuring 90 Designs. NOVATO, Calif., Nov. 18, 2024 /PRNewswire/ - Zenni Optical, the world's leading online eyewear retailer, is thrilled to unveil the Jrue Holiday x Zenni Collection exclusively at Zenni.com. This collaboration marks an exciting step for Zenni, following the announcement in June of Jrue Holiday as the brand's newest ambassador. Known for his on-court precision and off-court elegance, Jrue brings a fresh and modern approach to eyewear, curating a selection of frames that are practical and fashion-forward.
Document Source: https://www.prnewswire.com/news-releases/zenni-optical-and-nba-star-jrue-holiday-team-up-to-launch-exclusive-eyewear-collection-302308003.html
(archive.org page /
archive.org listing)
Document Date: Nov. 18, 2024, 2 p.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership:
Document Extract: Zenni partners with Jrue Holiday, the star guard, 2x NBA champion, 2x All-Star and 2x Olympian for a Stylish Eyewear Launch Featuring 90 Designs. NOVATO, Calif., Nov. 18, 2024 /PRNewswire/ - Zenni Optical, the world's leading online eyewear retailer, is thrilled to unveil the Jrue Holiday x Zenni Collection exclusively at Zenni.com. This collaboration marks an exciting step for Zenni, following the announcement in June of Jrue Holiday as the brand's newest ambassador. Known for his on-court precision and off-court elegance, Jrue brings a fresh and modern approach to eyewear, curating a selection of frames that are practical and fashion-forward. Photo courtesy of Zenni Optical.
Document Source: https://www.prnewswire.com/news-releases/zenni-optical-and-nba-star-jrue-holiday-team-up-to-launch-exclusive-eyewear-collection-302308003.html
(archive.org page /
archive.org listing)
Document Date: Nov. 18, 2024, 1 p.m. / Source: Fierce Biotech
Activity Class: PartnershipActivity
/ Region: Boston
Partnership:
- Novartis
/ Industry: Biopharmaceutical And Biotech Industry, Biotech And Technology and 15 more
- Ratio
/ Industry: Biotech And Technology, Fintech Services and 1 more
- Ratio
/ Industry: Biotech And Technology, Fintech Services and 1 more
- Novartis
/ Industry: Biopharmaceutical And Biotech Industry, Biotech And Technology and 15 more
Document Extract: Novartis, Ratio sign radiopharmaceutical pact to the tune of $ 745M biobucks. Novartis is adding another radiopharmaceutical program to its collection, penning a deal worth $ 745 million in biobucks for rights to a cancer candidate from Ratio Therapeutics. Boston - based biotech Ratio and Novartis will work together researching and selecting a somatostatin receptor 2 (SSTR2) -targeting development candidate, according to a Nov. 18 release. From there, Novartis will take on the rest of the responsibilities around the asset, including further development and potential commercialization activities. The worldwide licensing agreement will leverage Ratio's radioligand tech platforms, which are designed to develop fit-for-purpose radiopharmaceuticals for therapy and imaging.
Document Source: https://www.fiercebiotech.com/biotech/novartis-ratio-sign-radiopharmaceutical-pact-tune-745m-biobucks
(archive.org page /
archive.org listing)
Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.
Treat sameAsNameOnly relationship as same? No
(Turn On)
Site Stats
| About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License.
Please send an email if you need a non-share-alike license and/or you need API access.